Explore Our Biomarker Menu

Biomarker:

VEGF-D

Biological or Clinical Significance:

C-fos-induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGF-D) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene. The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor C. VEGF-D has been established to be over-expressed in both tumor tissues and patients’ serum samples in several types of human cancer. In addition, VEGF-D expression has been implicated with increased incidence of regional lymph node metastasis. VEGF-D serum levels are significantly elevated in patients with angiosarcoma.

References:

Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG (Feb 2001). “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics”. Nature Medicine 7 (2): 186–91. doi:10.1038/84635. PMID 11175849.

Analyte:

VEGF-D

Matrix:

Human K2 EDTA Plasma

Status:

Validated

Sensitivity-LLOQ:

39.4 pg/mL

Sensitivity-ULOQ:

35,286 pg/mL

platform

MSD-ECL

Required Sample Volume

50 µL/well

Disease State:

Oncology

MSD Panel:

Angiogenesis Panel 1 (Human)

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.